학술논문

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Document Type
Article
Source
Annals of Oncology. Jul2019, Vol. 30 Issue 7, p1180-1180. 1p.
Subject
*BREAST cancer
*HORMONE receptor positive breast cancer
*MEDICAL societies
Language
ISSN
0923-7534